Effect of moclobemide on clinical and neurochemical variables in depressed patients (preliminary findings).
In this paper the preliminary results from an ongoing investigation on the effect of the MAO-A inhibitor moclobemide on clinicolaboratory variables (antidepressant effect, platelet MAO activity, urinary MHPG and 5-HIAA excretion, plasma prolactin and growth hormone levels and TSH response to TRH) are reported. From the total of 18 patients, 10 (2 males and 8 females) responded favourably (reduction in the HDRS 50% or more) to the treatment. Urine MHPG excretion significantly (p less than 0.001) decreased during treatment, while 5-HIAA secretion showed a less pronounced decrease (p less than 0.05). Plasma PRL and GH remained unchanged, while the TSH-response to TRH increased significantly (p less than 0.025) after 4-week treatment. A significant correlation was found between MHPG pretreatment values and treatment outcome.